.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Decitabine is a critical DNA hypomethylating agent used for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Traditionally, its poor oral decitabine bioavailability required patients to undergo frequent intravenous infusions. However, the development of a fixed-dose combination with cedazuridine has revolutionized treatment options. This oral medication achieves systemic exposure equivalent to intravenous therapy by preventing the rapid degradation of decitabine in the digestive system and liver.
While clinicians primarily attribute the boost in oral decitabine bioavailability to the inhibition of cytidine deaminase (CDA), recent research suggests a more complex interaction. Cedazuridine effectively blocks first-pass metabolism in the gut and liver, where CDA usually degrades decitabine. Furthermore, new evidence shows that cedazuridine influences renal elimination. By interacting with the concentrative nucleoside transporter 1 (CNT1) in the kidneys, cedazuridine reduces the renal clearance of decitabine. Consequently, this dual mechanism ensures more consistent and higher drug levels in the bloodstream, mimicking the effects of a continuous infusion.
Understanding these pharmacokinetic drivers is essential for optimizing patient outcomes in hematological care. The interplay between CDA inhibition and renal transporter modulation highlights why this combination is so effective. Additionally, it provides a scientific framework for predicting potential drug-drug interactions involving renal transport pathways. As more oral therapies enter the oncology space, these insights will help clinicians manage treatment protocols more precisely for patients in India and worldwide.
Decitabine has very poor oral decitabine bioavailability on its own because the enzyme cytidine deaminase (CDA) quickly breaks it down in the digestive tract and liver before it reaches the bloodstream.
Cedazuridine acts as a potent CDA inhibitor, protecting decitabine from early degradation. It also affects renal transporters like CNT1, which helps maintain therapeutic levels of the drug by reducing its loss through urine.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional clinical judgment or direct patient care. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A recent study identifies CDA inhibition and CNT1-mediated tubular reabsorption as key drivers of oral decitabine's improved bioavailability with cedazuridi...
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
